Document:

THIS  WARRANT  HAS BEEN,  AND THE SHARES OF COMMON  STOCK  WHICH MAY BE RECEIVED
PURSUANT TO THE EXERCISE OF THIS WARRANT WILL BE, ACQUIRED SOLELY FOR INVESTMENT
AND NOT WITH A VIEW TO,  OR FOR  RESALE IN  CONNECTION  WITH,  ANY  DISTRIBUTION
THEREOF.  NEITHER THIS WARRANT NOR SUCH SHARES (TOGETHER, THE "SECURITIES") HAVE
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY
STATE  SECURITIES  LAWS.  SUCH  SECURITIES  MAY NOT BE SOLD,  OFFERED  FOR SALE,
PLEDGED OR  HYPOTHECATED  IN THE ABSENCE OF SUCH  REGISTRATION  OR AN OPINION OF
COUNSEL  REASONABLY  SATISFACTORY TO THE COMPANY THAT SUCH DISPOSITION IS EXEMPT
FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE ACT AND OF ANY
APPLICABLE STATE SECURITIES LAWS.

NO. WA2-                                              ISSUED:     APRIL 8, 2004

                      A-2 WARRANT TO PURCHASE COMMON STOCK

                                   ----------

      THIS CERTIFIES  THAT, for good and valuable  consideration,  [see attached
schedule] (the "HOLDER") is entitled to purchase from Adventrx  Pharmaceuticals,
Inc., a Delaware  corporation  (the  "COMPANY"),  [20%  Coverage]  [see attached
schedule] fully paid and nonassessable  shares of Common Stock, par value $0.001
per share ("COMMON  STOCK"),  of the Company (as adjusted  pursuant to Section 3
hereof)  (the  "WARRANT  SHARES")  at a price per share equal to Two Dollars and
Fifty Cents  ($2.50) (as adjusted  pursuant to Section 3 hereof) (the  "EXERCISE
PRICE"), subject to the provisions and upon the terms and conditions hereinafter
set forth.

1. METHOD OF EXERCISE; PAYMENT.

      (a) Exercise Period. The purchase right represented by this Warrant may be
exercised in whole or part by the Holder during the term of this Warrant (as set
forth in Section 9 hereof) at any time after the  Commencement  Date, as defined
below,  by the  surrender  of this  Warrant  (with the notice of  exercise  form
attached  hereto as Exhibit A (the "NOTICE OF EXERCISE")  duly  executed) at the
principal  office of the Company.  If this Warrant shall have been  exercised in
part,  the  Company  shall,  at the  time  of  delivery  of the  certificate  or
certificates  representing  Warrant Shares,  deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased shares of Common
Stock called for by this Warrant,  which new Warrant shall in all other respects
be identical  with this  Warrant,  or at the request of the Holder,  appropriate
notation may be made on this Warrant and the same returned to the Holder.

      (b)  Exercise.  Upon  exercise of this  Warrant,  the Holder shall pay the
Company an amount equal to the product of (x) the Exercise  Price  multiplied by
(y) the total number of Warrant Shares  purchased  pursuant to this Warrant,  by
wire transfer or certified  check payable to the order of the Company or, at any
time  following  the first  anniversary  of the Warrant Date, if there is not an
effective Registration Statement (as defined in the Registration Rights

<PAGE>

Agreement,  dated as of the Warrant Date,  among the Company and the persons and
entities listed on Schedule 1 thereto (the "REGISTRATION RIGHTS AGREEMENT") with
respect to all of the Warrant  Shares,  then at the option of the  Holder,  such
amount may be paid by the  surrender of a portion of shares of Common Stock then
held by the Holder or issuable upon such  exercise of this Warrant,  which shall
be valued and credited toward such amount due to the Company for the exercise of
the Warrant based upon the Current Market Price of the Common Stock.  The person
or persons in whose name(s) any  certificate(s)  representing the Warrant Shares
shall be issuable  upon  exercise of this Warrant shall be deemed to have become
the  holder(s) of record of, and shall be treated for all purposes as the record
holder(s) of, the Warrant  Shares  represented  thereby (and such Warrant Shares
shall be deemed to have been issued)  immediately prior to the close of business
on the date upon which this Warrant is exercised.

      "CURRENT  MARKET PRICE" means,  in respect of any share of Common Stock on
any date herein specified,

      (1) if there shall not then be a public market for the Common  Stock,  the
higher of

      (a) the book value per share of Common Stock at such date, and

      (b) the value per share of Common Stock at such date as determined in good
faith by the Board,

      or

      (2) if there  shall  then be a public  market for the  Common  Stock,  the
higher of (x) the book value per share of Common Stock at such date, and (y) the
average  of the  daily  market  prices  for  the  10  consecutive  trading  days
immediately  before such date. The daily market price (the "DAILY MARKET PRICE")
for each  such  trading  day shall be (i) the  closing  price on such day on the
principal stock exchange  (including  Nasdaq) on which such Common Stock is then
listed or admitted to trading,  or quoted, as applicable,  (ii) if no sale takes
place on such day on any such exchange,  the last reported closing price on such
day as officially quoted on any such exchange (including  Nasdaq),  (iii) if the
Common  Stock is not then listed or  admitted to trading on any stock  exchange,
the last reported closing bid price on such day in the over-the-counter  market,
as  furnished  by the  National  Association  of  Securities  Dealers  Automatic
Quotation System or the National  Quotation  Bureau,  Inc., (iv) if neither such
corporation at the time is engaged in the business of reporting such prices,  as
furnished by any similar firm then engaged in such business,  or (v) if there is
no such  firm,  as  furnished  by any  member  of the  National  Association  of
Securities  Dealers,  Inc. (the "NASD") selected  mutually by the holder of this
Warrant  and the  Company  or, if they  cannot  agree  upon such  selection,  as
selected  by two such  members of the NASD,  one of which  shall be  selected by
holder of this Warrant and one of which shall be selected by the Company.

      (c) Stock  Certificates.  In the event of the  exercise  of this  Warrant,
certificates  for the Warrant  Shares so  purchased  shall be  delivered  to the
Holder within a reasonable  time after  exercise,  but in no case later than the
date that is three business days following receipt by the Company of a Notice of
Exercise duly completed and executed.

                                      -2-
<PAGE>

      2. STOCK  FULLY PAID;  RESERVATION  OF SHARES.  All of the Warrant  Shares
issuable upon the exercise of the rights  represented by this Warrant will, upon
issuance  and  receipt  of the  Exercise  Price  therefor,  be  fully  paid  and
nonassessable,  and free from all preemptive rights,  rights of first refusal or
first offer,  taxes,  liens and charges  with  respect to the issuance  thereof.
During the period  within  which the rights  represented  by this Warrant may be
exercised,  the Company  shall at all times have  authorized  and  reserved  for
issuance a  sufficient  number of shares of its Common  Stock to provide for the
exercise of the rights represented by this Warrant.

      3. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF SHARES.  The number and kind
of Warrant Shares purchasable upon the exercise of this Warrant and the Exercise
Price  therefor  shall be  subject  to  adjustment  from  time to time  upon the
occurrence of certain events, as follows:

      (a)  Reclassification,  Consolidation  or  Reorganization.  In case of any
reclassification  of the Common Stock (other than a change in par value, or as a
result of a subdivision  or  combination),  or in case of any  consolidation  or
merger of the Company with or into another  corporation  (other than a Change of
Control, as defined below) (any of which is a "REORGANIZATION TRANSACTION"), the
Company,  or such successor  corporation as the case may be, shall execute a new
warrant,  providing  that the Holder  shall have the right to exercise  such new
warrant,  and  procure  upon such  exercise  and  payment of the same  aggregate
Exercise Price, in lieu of the Warrant Shares theretofore issuable upon exercise
of this Warrant, the kind and amount of shares of stock, other securities, money
and property as would be payable for the Warrant  Shares  issuable upon exercise
of this Warrant as if such Warrant Shares were  outstanding on the  consummation
of the  Reorganization  Transaction.  For  purposes  of this  Warrant,  the term
"CHANGE OF CONTROL"  shall mean (i) any  acquisition  of the Company by means of
merger,  acquisition,  or  other  form  of  corporate  reorganization  in  which
outstanding  shares  of the  Company  are  exchanged  for  securities  or  other
consideration  issued, or caused to be issued,  by the acquiring  corporation or
its subsidiary or parent (other than a reincorporation  transaction or change of
domicile) and pursuant to which the holders of the outstanding voting securities
of the  Company  immediately  prior  to  such  consolidation,  merger  or  other
transaction fail to hold equity securities representing a majority of the voting
power  of  the  Company  or  surviving   entity   immediately   following   such
consolidation,  merger or other transaction  (excluding voting securities of the
acquiring  corporation held by such holders prior to such transaction) or (ii) a
sale of all or substantially all of the assets of the Company.

      (b) Stock  Splits,  Dividends  and  Combinations.  In the  event  that the
Company shall at any time subdivide the  outstanding  shares of Common Stock, or
shall issue a stock  dividend on its  outstanding  shares of Common  Stock,  the
number of Warrant  Shares  issuable  upon  exercise of this Warrant  immediately
prior to such  subdivision  or to the issuance of such stock  dividend  shall be
proportionately  increased,  and the  Exercise  Price  shall be  proportionately
decreased,  and in the event  that the  Company  shall at any time  combine  the

                                      -3-
<PAGE>

outstanding  shares of Common Stock,  the number of Warrant Shares issuable upon
exercise  of this  Warrant  immediately  prior  to  such  combination  shall  be
proportionately  decreased,  and the  Exercise  Price  shall be  proportionately
increased,  effective at the close of business on the date of such  subdivision,
stock dividend or combination, as the case may be.

      (c) Issuance of Additional Shares.

          (i) If at any time while this  Warrant is  outstanding  and after June
          30,  2004,  the  Company  shall issue or sell any shares of its Common
          Stock,  other than  Excluded  Shares  (as that term is defined  below)
          ("ADDITIONAL  SHARES"), in exchange for consideration in an amount per
          Additional  Share  less  than  the  Exercise  Price  at the  time  the
          Additional  Shares  are  issued  or  sold,  then  the  Exercise  Price
          immediately  prior to such  issue or sale  shall be reduced to a price
          determined by dividing:

                  (1) an amount  equal to the sum of (a) the number of shares of
                  Common Stock  outstanding  immediately  prior to such issue or
                  sale multiplied by the then existing  Exercise Price, plus (b)
                  the  consideration,  if any, received by the Company upon such
                  issue or sale, by

                  (2) the total  number of  shares of Common  Stock  outstanding
                  immediately after such issue or sale.

          (ii) The  provisions of Section  3(c)(i) shall not apply to any deemed
          issuance  of  Additional  Shares for which an  adjustment  is provided
          under  Section 3(a) or 3(b).  No adjustment of the number of shares of
          Common Stock  acquirable  upon  exercise of this Warrant shall be made
          under  Section  3(c) upon the  issuance of any shares of Common  Stock
          which are issued  pursuant to the  exercise  of any  warrants or other
          subscription  or purchase  rights or  pursuant to the  exercise of any
          conversion or exchange  rights in any convertible  securities,  if any
          such adjustment  shall  previously have been made upon the issuance of
          such warrants or other rights or upon the issuance of such convertible
          securities  (or upon  the  issuance  of any  warrant  or other  rights
          therefor) pursuant to Section 3(d).

For purposes of this Warrant the term  "EXCLUDED  SHARES"  means:  (i) shares of
Common Stock  issuable or issued after the Closing Date to officers,  employees,
consultants  or  directors  of the  Company  directly  or  pursuant  to a  stock
purchase,  stock option,  restricted stock or other written compensation plan or
agreement approved by the Board of Directors of the Company (the "BOARD");  (ii)
shares of Common Stock issued or issuable after the Closing Date,  primarily for
non-equity  financing  purposes  and as  approved  by the  Board,  to  financial
institutions  or lessors in  connection  with  commercial  credit  arrangements,
equipment  financings or similar transactions or to vendors of goods or services
or  customers;  (iii)  shares of Common  Stock  issuable  upon (a)  exercise  of
warrants,  options,  notes or other rights to acquire securities of the Company,
in each case,  outstanding  on the issuance  date of this Warrant (the  "WARRANT
DATE"),  (b) conversion of shares of the Company's  Preferred  Stock,  par value
$0.01 per share,  outstanding  on the Warrant  Date,  (c) exchange of promissory
notes issued by the Company outstanding on the Warrant Date, (iv) the Shares (as
such term is defined in the Common Stock and Warrant Purchase  Agreement,  dated
as of the Warrant Date, among the Company and the persons and entities listed on

                                      -4-
<PAGE>

Schedule 1 thereto (the "PURCHASE  AGREEMENT"));  (v) the Warrants (as such term
is defined in the Purchase Agreement); (vi) capital stock or warrants or options
to purchase  capital  stock issued in  connection  with bona fide  acquisitions,
mergers or similar  transactions,  the terms of which are approved by the Board;
(vii) shares of Common Stock  issued or issuable to licensors of  technology  of
the Company to pay  expenses,  royalties  or  milestone  payments  for which the
Company is obligated under any licensing or related agreement;  (viii) shares of
Common Stock issuable or issued  pursuant to stock splits,  stock  dividends and
the like,  or (ix) shares of Common  Stock issued or issuable by way of dividend
or other distribution on Excluded Shares.

      (d) Issuance of Common Stock Equivalents.

          (i) If at any time while this Warrant is outstanding the Company shall
          issue or sell  any  warrants  or  other  rights  to  subscribe  for or
          purchase  any  additional  shares  of Common  Stock or any  securities
          convertible  into shares of Common  Stock  (other than the  Additional
          Shares) (collectively, "COMMON STOCK EQUIVALENTS"), whether or not the
          rights to exchange or convert thereunder are immediately  exercisable,
          and the  effective  price per share for which Common Stock is issuable
          upon  the  exercise,  exchange  or  conversion  of such  Common  Stock
          Equivalents   shall  be  less  than  the  Exercise   Price  in  effect
          immediately prior to the time of such issue or sale, then the Exercise
          Price shall be adjusted as provided in Section  3(c) on the basis that
          the  maximum  number of  additional  shares of Common  Stock  issuable
          pursuant to all such Common Stock  Equivalents shall be deemed to have
          been issued and outstanding and the Company shall have received all of
          the  consideration  payable  therefor,  if any,  as of the date of the
          actual  issuance  of  such  Common  Stock   Equivalents.   No  further
          adjustments  to the  current  Warrant  Price  shall be made under this
          Section  3(d) upon the  actual  issue of such  Common  Stock  upon the
          exercise, conversion or exchange of such Common Stock Equivalents.

          (ii) Upon the  expiration  or  termination  of any such  Common  Stock
          Equivalents,  the Exercise Price, to the extent in any way affected by
          or computed using such Common Stock  Equivalents,  shall be recomputed
          to reflect the  issuance of the total number of shares of Common Stock
          (and  convertible or exchangeable  securities  which remain in effect)
          actually  issued upon the  exercise,  exchange or  conversion  of such
          Common  Stock  Equivalents  to the  extent  that this  Warrant is then
          outstanding.

      (e) Other Action  Affecting Common Stock. In case at any time or from time
to time the Company shall take any action in respect of its Common Stock,  other
than the  payment  of  dividends  permitted  by  Section 3 or any  other  action
described  in Section 3, then,  unless such  action  will not have a  materially
adverse  effect  upon the rights of the  Holder,  the number of shares of Common
Stock or other stock into which this Warrant is exercisable  and/or the purchase
price  thereof  shall be  adjusted  in such  manner as may be  equitable  in the
circumstances.

                                      -5-
<PAGE>

      (f) Certificate as to Adjustments.  Upon the occurrence of each adjustment
or  readjustment  of the  Exercise  Price,  the Company,  at its expense,  shall
promptly  compute such  adjustment or  readjustment in accordance with the terms
hereof and  prepare  and  furnish to the  Holder of this  Warrant a  certificate
setting forth such  adjustment or  readjustment  and showing in detail the facts
upon which such adjustment or readjustment is based. The Company shall, upon the
written  request at any time of the Holder of this Warrant,  furnish or cause to
be  furnished  to  such  Holder  a  like  certificate  setting  forth  (i)  such
adjustments and readjustments, (ii) the Exercise Price at the time in effect and
(iii) the  number of shares of Common  Stock and the  amount,  if any,  or other
property which at the time would be received upon the exercise of Warrants owned
by such Holder.

      (g) Notice of Corporate Action. If at any time:

          (i) the Company shall take a record of the holders of its Common Stock
for the  purpose of  entitling  them to receive a  dividend  (other  than a cash
dividend  payable out of earnings or earned  surplus  legally  available for the
payment of dividends under the laws of the  jurisdiction of incorporation of the
Company) or other  distribution,  or any right to subscribe  for or purchase any
evidences  of its  indebtedness,  any  shares of stock of any class or any other
securities or property, or to receive any other right, or

          (ii) there shall be any capital  reorganization  of the  Company,  any
reclassification  or recapitalization of the capital stock of the Company or any
consolidation  or merger of the  Company  with,  or any sale,  transfer or other
disposition of all or substantially all the property,  assets or business of the
Company to, another corporation, or

          (iii)  there  shall  be  a  voluntary  or   involuntary   dissolution,
liquidation or winding up of the Company;

then, in any one or more of such cases, the Company shall give to the Holder (i)
at least  10-days' prior written notice of the date on which a record date shall
be selected for such dividend,  distribution or right or for determining  rights
to  vote  in  respect  of any  such  reorganization,  reclassification,  merger,
consolidation, sale, transfer, disposition,  dissolution, liquidation or winding
up, and (ii) in the case of any such reorganization,  reclassification,  merger,
consolidation, sale, transfer, disposition,  dissolution, liquidation or winding
up, at least  10-days' prior written notice of the date when the same shall take
place.  Such notice in accordance  with the foregoing  clause also shall specify
(i) the date on which any such  record is to be taken  for the  purpose  of such
dividend,  distribution or right,  the date on which the holders of Common Stock
shall be entitled to any such dividend,  distribution  or right,  and the amount
and  character  thereof,  and (ii) the  date on which  any such  reorganization,
reclassification,    merger,   consolidation,   sale,   transfer,   disposition,
dissolution,  liquidation  or winding  up is to take place and the time,  if any
such  time is to be fixed,  as of which the  holders  of Common  Stock  shall be
entitled  to  exchange  their  shares of Common  Stock for  securities  or other
property  deliverable  upon  such  reorganization,   reclassification,   merger,
consolidation, sale, transfer, disposition,  dissolution, liquidation or winding
up. Each such  written  notice shall be  sufficiently  given if addressed to the
Holder at the last  address of the Holder  appearing on the books of the Company
and delivered in accordance with Section 11(d).

                                      -6-
<PAGE>

4. TRANSFER OF WARRANT.  This Warrant may only be transferred in compliance with
federal  and state  securities  laws;  provided,  however,  that the Company may
withhold its consent to transfer or  assignment of this Warrant to any person or
entity  who is  deemed  to be a  competitor  or  prospective  competitor  of the
Company,  such determination to be made in the reasonable judgment of the Board.
If, at the time of the surrender of this Warrant in connection with any transfer
of this Warrant or the resale of the Warrant Stock,  this Warrant or the Warrant
Stock,  as applicable,  shall not be registered  under the  Securities  Act, the
Company may  require,  as a condition  of allowing  such  transfer  (i) that the
Holder or  transferee  of this Warrant or the Warrant  Stock as the case may be,
furnish  to the  Company  a  written  opinion  of  counsel  that  is  reasonably
acceptable  to the Company to the effect that such  transfer may be made without
registration  under  the  Securities  Act,  (ii) that the  Holder or  transferee
execute and deliver to the Company an  investment  letter in form and  substance
acceptable  to the Company and  substantially  in the form attached as Exhibit B
hereto and (iii) that the transferee be an  "accredited  investor" as defined in
Rule 501(a)  promulgated  under the Securities Act. Transfer of this Warrant and
all rights  hereunder,  in whole or in part,  in  accordance  with the foregoing
provisions, shall be registered on the books of the Company to be maintained for
such  purpose,  upon  surrender of this Warrant at the  principal  office of the
Company or the  office or agency  designated  by the  Company,  together  with a
written assignment of this Warrant substantially in the form of Exhibit C hereto
duly executed by the Holder or its  attorney-in-fact and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required,  such  payment,  the Company  shall  execute and deliver a new
Warrant  or  Warrants  in the  name  of the  assignee  or  assignees  and in the
denomination specified in such instrument of assignment,  and shall issue to the
assignor a new Warrant  evidencing  the portion of this Warrant not so assigned,
and this Warrant shall promptly be cancelled. Following a transfer that complies
with the  requirements  of this Section 4, the Warrant may be exercised by a new
Holder for the  purchase  of shares of Common  Stock  regardless  of whether the
Company  issued or  registered a new Warrant on the books of the  Company.  This
Section 4 shall survive the exercise or expiration of the Warrant.

5. CONDITIONS TO EXERCISE OF WARRANT.

      (a) Each certificate evidencing the Warrant Shares issued upon exercise of
this Warrant shall be stamped or imprinted  with a legend  substantially  in the
following form:

          THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
          UNDER THE  SECURITIES  ACT OF 1933 (THE "ACT") AND MAY NOT
          BE  OFFERED,  SOLD OR  OTHERWISE  TRANSFERRED,  PLEDGED OR
          HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR,
          IN  THE   OPINION  OF   COUNSEL  IN  FORM  AND   SUBSTANCE
          SATISFACTORY  TO THE  ISSUER  OF  THESE  SECURITIES,  SUCH
          OFFER,  SALE OR TRANSFER,  PLEDGE OR  HYPOTHECATION  IS IN
          COMPLIANCE THEREWITH.

                                      -7-
<PAGE>

      (b) REMOVAL OF LEGEND AND TRANSFER RESTRICTIONS.  Any legend endorsed on a
certificate  pursuant to this Section 5 shall be removed,  and the Company shall
issue a certificate  without such legend to the holder of such Warrant Shares if
(i) such Warrant Shares are resold  pursuant to a registration  statement  under
the  Securities  Act  of  1933,  as  amended,   and  a  prospectus  meeting  the
requirements  of  Section  10 of the  Securities  Act  is  delivered  or  deemed
delivered to the purchaser of such Warrant Shares, (ii) if such holder satisfies
the  requirements  of Rule 144(k) or (iii) if such holder  provides  the Company
with an opinion of counsel  for such holder of the  Warrant  Shares,  reasonably
satisfactory to the Company,  to the effect that a sale,  transfer or assignment
of such Warrant Shares may be made without  registration.  This paragraph  shall
survive any exercise of this Warrant.

      (c)  RESTRICTIONS  ON  EXERCISE  AMOUNT.  Unless a Holder  delivers to the
Company  irrevocable  written notice (x) prior to the date of issuance hereof or
61 days prior to the effective  date of such notice that this Section 5(c) shall
not apply to such Holder or (y) prior to a Change of Control, the Holder may not
acquire a number of Warrant Shares to the extent that,  upon such exercise,  the
number of shares of Common Stock then beneficially  owned by such Holder and its
affiliates  and any other  persons or entities  whose  beneficial  ownership  of
Common Stock would be aggregated with the Holder's for purposes of Section 13(d)
of the  Securities  Exchange  Act of 1934,  as  amended  (the  "EXCHANGE  ACT"),
(including  shares  held by any  "group"  of which the  Holder is a member,  but
excluding shares  beneficially owned by virtue of the ownership of securities or
rights to acquire  securities  that have  limitations  on the right to  convert,
exercise or purchase  similar to the limitation set forth herein)  exceeds 9.99%
of the total  number of shares of Common  Stock of the  Company  then issued and
outstanding.  For purposes hereof,  "group" has the meaning set forth in Section
13(d) of the Exchange Act and applicable regulations of the Commission,  and the
percentage  held by the holder shall be determined in a manner  consistent  with
the  provisions  of Section 13(d) of the Exchange Act. Each delivery of a notice
of exercise by a Holder will constitute a representation  by such Holder that it
has evaluated the limitation set forth in this paragraph and  determined,  based
on the most recent public filings by the Company with the  Commission,  that the
issuance  of the full  number of  Warrant  Shares  requested  in such  notice of
exercise is permitted under this paragraph.

      6.  FRACTIONAL  SHARES.  No  fractional  Warrant  Shares will be issued in
connection with any exercise  hereunder,  but in lieu of such fractional  shares
the Company  shall make a cash payment  therefor  upon the basis of the Exercise
Price then in effect.

      7.  REGISTRATION  RIGHTS.  The Holder shall have the  registration  rights
described in the Registration Rights Agreement.

      8.  RIGHTS OF  STOCKHOLDERS.  No Holder  shall be  entitled,  as a Warrant
holder,  to vote or receive  dividends or be deemed the holder of Warrant Shares
or any other  securities of the Company which may at any time be issuable on the
exercise  hereof  for any  purpose,  nor  shall  anything  contained  herein  be
construed  to confer upon the Holder any of the rights of a  stockholder  of the
Company or any right to vote for the  election of  directors  or upon any matter
submitted to stockholders at any meeting thereof, or to give or withhold consent
to any corporate action (whether upon any  recapitalization,  issuance of stock,
reclassification  of  stock,  change  of  par  value,   consolidation,   merger,
conveyance,  or otherwise)  or to receive  dividends or  subscription  rights or

                                      -8-
<PAGE>

otherwise  with respect to the Warrant Shares until this Warrant shall have been
exercised and the Warrant Shares purchasable upon the exercise hereof shall have
become deliverable, as provided herein.

9. TERM OF WARRANT.  This Warrant shall become  exercisable  on the Warrant Date
and shall no longer be  exercisable  as of the  earlier  of (i) 5:00  p.m.,  San
Diego,  California local time, on the date that is the five-year  anniversary of
the Warrant Date; and (ii) upon consummation of a Change of Control.

10.  REDEMPTION  AT  COMPANY'S  ELECTION.  The  Company may at the option of the
Board,  by at  least  seven-days'  prior  written  notice  to  the  Holder  (the
"REDEMPTION  NOTICE"),  redeem this  Warrant,  in whole or in part, at any time,
provided that (i) the Daily Market Price for twenty consecutive  trading days is
equal to or greater  than the product of (x) 2  multiplied  by (y) the  Exercise
Price,  (ii) either (A) all of the Warrant Shares  underlying this Warrant to be
redeemed are then registered  under an effective  registration  statement or (B)
may  be  sold  pursuant  to  Rule  144  during  a  three-month   period  without
registration  under the Securities Act, (iii) sufficient  shares of Common Stock
of the Company are  authorized  and reserved for issuance upon the full exercise
of this Warrant,  (iv) all of the Warrant Shares  issuable upon exercise of this
Warrant  are then listed on every stock  exchange,  market or bulletin  board on
which any Common  Stock of the Company is then listed and (v) the Company is not
in default of any material provision of any Transaction Agreement (as defined in
the Purchase Agreement).  The Redemption Notice shall set forth a date, not less
than seven days after the date of the Redemption Notice, on which the redemption
of this Warrant shall occur (the "REDEMPTION DATE"). On the Redemption Date, (i)
the  Company  shall pay the  Holder by  certified  check an amount  equal to the
product  of (x) $0.001 (as  adjusted  in  proportion  to any  adjustment  to the
Exercise  Price  pursuant to Section 3 hereof)  multiplied  by (y) the number of
Warrant Shares so redeemed;  and (ii) the Holder shall deliver the original copy
of this Warrant  marked  "REDEEMED" to the Company.  If the Company shall redeem
this Warrant in part, the Company shall, at the Redemption  Date,  provided that
the  Holder  shall have  delivered  the  original  copy of this  Warrant  marked
"REDEEMED" to the Company,  deliver to the Holder a new Warrant  evidencing  the
rights of the Holder to purchase  the  unredeemed  shares of Common Stock called
for by this Warrant,  which new Warrant shall in all other respects be identical
with this Warrant.  Nothing in this Section 10 shall prevent the exercise of the
Warrants at any time prior to the Redemption Date.

11. MISCELLANEOUS.

      (a) This Warrant is being  delivered in the State of California  and shall
be  construed  and enforced in  accordance  with and governed by the laws of the
State of California, without giving effect to principles of conflicts of laws.

      (b) The headings in this Warrant are for purposes of reference  only,  and
shall not limit or otherwise affect any of the terms hereof.

      (c) The terms of this Warrant shall be binding upon and shall inure to the
benefit of any successors or assigns of the Company and of the Holder and of the
Warrant Shares issued or issuable upon the exercise hereof.

                                      -9-
<PAGE>

      (d) Any notice  provided  for or  permitted  under this  Warrant  shall be
treated as having been given (a) upon receipt, when delivered personally or sent
by  confirmed  facsimile or telecopy,  (b) one day after  sending,  when sent by
commercial  overnight courier with written verification of receipt, or (c) three
business days after deposit with the United States Postal  Service,  when mailed
postage  prepaid by certified or  registered  mail,  return  receipt  requested,
addressed (a) if to the Company, at 9948 Hibert Street, Suite 100, San Diego, CA
92131, facsimile:  (858) 271-9678,  Attention:  Nicholas J. Virca, or, if to the
Holder,  at such address or facsimile  number as the Holder shall have furnished
to the Company in  writing,  or at such other place of which the other party has
been notified in accordance with the provisions of this Section 11(d).

      (e)  This  Warrant  constitutes  the  full and  entire  understanding  and
agreement between the parties with regard to the subjects hereof.

      (f) Upon receipt of evidence reasonably satisfactory to the Company of the
loss,  theft,  destruction or mutilation of this Warrant and, in the case of any
such  loss,  theft or  destruction,  upon  delivery  of an  indemnity  agreement
reasonably satisfactory in form and amount to the Company or, in the case of any
such mutilation, upon surrender and cancellation of such Warrant, the Company at
the Holder's  expense will execute and deliver to the holder of record,  in lieu
thereof, a new Warrant of like date and tenor.

      (g) This  Warrant  and any  provision  hereof  may be  amended,  waived or
terminated  only by an  instrument  in  writing  signed by the  Company  and the
Holder.

      (h) Receipt of this Warrant by the Holder shall  constitute  acceptance of
and agreement to the foregoing terms and conditions.

                            [Signature page follows.]

                                      -10-
<PAGE>

         IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by
its duly authorized officer.

Issued: April 8, 2004

                                            ADVENTRX PHARMACEUTICALS, INC.

                                            By: /s/ Nicholas J. Virca
                                                -------------------------
                                                Nicholas J. Virca
                                                President & CEO

           SIGNATURE PAGE TO THE A-2 WARRANT TO PURCHASE COMMON STOCK

<PAGE>

                                    EXHIBIT A

                               NOTICE OF EXERCISE

TO:  Adventrx Pharmaceuticals, Inc.
     9948 Hibert Street, Suite 100
     San Diego, CA  92131

      1. The undersigned hereby elects to purchase ____________ shares of Common
Stock,  par value $0.001 per share, of the Company  ("COMMON STOCK") pursuant to
the terms of Section  1(b) of the A-2  Warrant to  Purchase  Common  Stock dated
___________ 2004 (the  "WARRANT"),  and tenders herewith payment of the purchase
price of such shares in full.

      2. The  undersigned  hereby  elects to convert the  attached  Warrant into
Common Stock of Adventrx  Pharmaceuticals,  Inc. through "cashless  exercise" in
the manner  specified in the Warrant.  This conversion is exercised with respect
to _____________________ of the Shares covered by the Warrant.

      Please issue a certificate  or  certificates  representing  said _________
shares of Common Stock in the name of the  undersigned  or in such other name as
is specified below:

                    Name:      _________________________________

                    Address:   _________________________________

                               ---------------------------------

      The undersigned  hereby  represents and warrants that the aforesaid shares
of Common  Stock are being  acquired  for the  account  of the  undersigned  for
investment  and not  with a view  to,  or for  resale,  in  connection  with the
distribution  thereof,  and that the  undersigned  has no present  intention  of
distributing  or  reselling  such  shares,  and  that  all  representations  and
warranties of the  undersigned  with respect to the Warrants and Warrant  Shares
(as defined in the Warrant) set forth in Section 4 of the Purchase Agreement (as
defined in the Warrant) were true and correct as of the Warrant Date (as defined
in the Warrant) and are true and correct as of the date hereof.

                                      --------------

                                      By:      _________________________________

                                      Name:    _________________________________

                                      Title:   _________________________________

                                      Date:    _________________________________

<PAGE>

                                    EXHIBIT B

                    FORM OF INVESTMENT REPRESENTATION LETTER

In connection with the acquisition of [warrants (the "Warrants") to purchase
_______ shares of Common Stock of Adventrx Pharmaceuticals, Inc. (the
"Company"), par value $0.001 per share (the "Common Stock")][________ shares of
Common Stock of Adventrx Pharmaceuticals, Inc. (the "Company"), par value $0.001
per share (the "Common Stock")], by _______________ (the "Holder") from
_____________, the Holder hereby represents and warrants to the Company as
follows:

The Holder (i) is an "Accredited Investor" as that term is defined in Rule 501
of Regulation D promulgated under the Securities Act of 1933, as amended (the
"Act"); and (ii) has the ability to bear the economic risks of such Holder's
prospective investment, including a complete loss of Holder's investment in the
Warrants and the shares of Common Stock issuable upon the exercise thereof
(collectively, the "Securities").

The Holder, by acceptance of the Warrants, represents and warrants to the
Company that the Warrants and all securities acquired upon any and all exercises
of the Warrants are purchased for the Holder's own account, and not with view to
distribution of either the Warrants or any securities purchasable upon exercise
thereof in violation of applicable securities laws.

The Holder acknowledges that (i) the Securities have not been registered under
the Act, (ii) the Securities are "restricted securities" and the certificate(s)
representing the Securities shall bear the following legend, or a similar legend
to the same effect, until (i) in the case of the shares of Common Stock
underlying the Warrants, such shares shall have been registered for resale by
the Holder under the Act and effectively been disposed of in accordance with a
registration statement that has been declared effective; or (ii) in the opinion
of counsel for the Company such Securities may be sold without registration
under the Act:

"[NEITHER] THE SECURITIES REPRESENTED BY THIS CERTIFICATE [NOR THE SECURITIES
INTO WHICH THEY ARE EXERCISABLE] HAVE [NOT] BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE "ACT"), AND ALL SUCH SECURITIES ARE SUBJECT TO
RESTRICTIONS ON TRANSFERABILITY AS SET FORTH IN THIS CERTIFICATE. [NEITHER] THE
SECURITIES REPRESENTED HEREBY [NOR THE SECURITIES INTO WHICH THEY ARE
EXERCISABLE] MAY [NOT] BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR AN OPINION OF
COUNSEL, REASONABLY ACCEPTABLE TO COUNSEL FOR THE COMPANY, TO THE EFFECT THAT
THE PROPOSED SALE, TRANSFER, OR DISPOSITION MAY BE EFFECTUATED WITHOUT
REGISTRATION UNDER THE ACT."

IN WITNESS WHEREOF, the Holder has caused this Investment Representation Letter
to be executed in its corporate name by its duly authorized officer this __ day
of __________ 200_.

[Name]

By:______________________________
Name:
Title:

<PAGE>

                                    EXHIBIT C

                                 ASSIGNMENT FORM

FOR VALUE RECEIVED the undersigned registered owner of this Warrant for the
purchase of shares of Common Stock of Adventrx Pharmaceuticals, Inc. hereby
sells, assigns and transfers unto the Assignee named below all of the rights of
the undersigned under this Warrant, with respect to the number of shares of
common stock set forth below:

---------------------------------------

---------------------------------------

---------------------------------------
(Name and Address of Assignee)

---------------------------------------
(Number of Shares of Common Stock)

and does hereby irrevocably constitute and appoint ____________ attorney-in-fact
to register such transfer on the books of the Company, maintained for the
purpose, with full power of substitution in the premises.

Dated:_________________________________

--------------------------------------
(Print Name and Title)

--------------------------------------
(Signature)

--------------------------------------
(Witness)

NOTICE: The signature on this assignment must correspond with the name as
written upon the face of the Warrant in every particular, without alteration or
enlargement or any change whatsoever.

<PAGE>

                           SCHEDULE OF WARRANTHOLDERS

                  ADVENTRX Pharmaceuticals, Inc. issued this form of A-2 Warrant
to Purchase Common Stock to each of the persons for the purchase of up to the
number of shares of Common Stock listed opposite such person's name below.

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------
HOLDER                                                                          WARRANT NO.         SHARES
-----------------------------------------------------------------------------------------------------------
<S>                                                                                <C>             <C>
Alpha Capital AG                                                                   WA2-1            66,666
-----------------------------------------------------------------------------------------------------------
Anasazi Partners III LLC                                                           WA2-2            23,333
-----------------------------------------------------------------------------------------------------------
Anasazi Partners III Offshore Fund Ltd.                                            WA2-3            23,333
-----------------------------------------------------------------------------------------------------------
Andrew J. Maffey                                                                   WA2-4             3,400
-----------------------------------------------------------------------------------------------------------
Bank Sal. Oppenheim jr. & Cie (Switzerland) Limited                                WA2-5             1,000
-----------------------------------------------------------------------------------------------------------
BayStar Capital II, L.P.                                                           WA2-6            40,000
-----------------------------------------------------------------------------------------------------------
Bristol Investment Fund, Ltd.                                                      WA2-7            53,333
-----------------------------------------------------------------------------------------------------------
BSI New BioMedical Frontier (SICAV)                                                WA2-8            20,000
-----------------------------------------------------------------------------------------------------------
BSI SA                                                                             WA2-9            19,900
-----------------------------------------------------------------------------------------------------------
Capital Ventures International                                                     WA2-10          133,333
-----------------------------------------------------------------------------------------------------------
Castle Creek Healthcare Partners LLC                                               WA2-11           66,666
-----------------------------------------------------------------------------------------------------------
CD Investment Partners, Ltd.                                                       WA2-60           50,000
-----------------------------------------------------------------------------------------------------------
Centrum Bank AG                                                                    WA2-57            6,000
-----------------------------------------------------------------------------------------------------------
Christopher P. Baker                                                               WA2-12           20,000
-----------------------------------------------------------------------------------------------------------
Clariden Investments Ltd.                                                          WA2-13            5,400
-----------------------------------------------------------------------------------------------------------
Crescent International Ltd                                                         WA2-14           36,000
-----------------------------------------------------------------------------------------------------------
Crestview Capital Master, LLC                                                      WA2-15          133,333
-----------------------------------------------------------------------------------------------------------
E Todd Tracy                                                                       WA2-16           20,000
-----------------------------------------------------------------------------------------------------------
Enable Growth Partners                                                             WA2-17           40,000
-----------------------------------------------------------------------------------------------------------
Gamma Opportunity Capital Partners, LP                                             WA2-18           53,333
-----------------------------------------------------------------------------------------------------------
Gene Salkind, MD                                                                   WA2-19           12,000
-----------------------------------------------------------------------------------------------------------
Greenwich Growth Fund Limited                                                      WA2-20           13,333
-----------------------------------------------------------------------------------------------------------
James Ladner                                                                       WA2-21            4,000
-----------------------------------------------------------------------------------------------------------
JIBS Equities                                                                      WA2-22           26,666
-----------------------------------------------------------------------------------------------------------
Kenneth Greif                                                                      WA2-23           66,666
-----------------------------------------------------------------------------------------------------------
Laddcap Value Partners LP                                                          WA2-24           20,000
-----------------------------------------------------------------------------------------------------------
LB (Swiss) Privatbank AG                                                           WA2-25            5,000
-----------------------------------------------------------------------------------------------------------
Lilienthal Investment Foundation                                                   WA2-26            6,800
-----------------------------------------------------------------------------------------------------------
Longview Fund, LP                                                                  WA2-27           33,333
-----------------------------------------------------------------------------------------------------------
Michael Loew                                                                       WA2-28            6,666
-----------------------------------------------------------------------------------------------------------
North Sound Legacy Fund LLC                                                        WA2-29            2,400
-----------------------------------------------------------------------------------------------------------
North Sound Legacy Institutional Fund LLC                                          WA2-30           26,400
-----------------------------------------------------------------------------------------------------------
North Sound Legacy International Ltd                                               WA2-31           51,200
-----------------------------------------------------------------------------------------------------------
OTAPE Investments LLC                                                              WA2-32           13,333
-----------------------------------------------------------------------------------------------------------
Paul Scharfer                                                                      WA2-33           27,000
-----------------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

<TABLE>
<CAPTION>
<S>                                                                                <C>             <C>
-----------------------------------------------------------------------------------------------------------
Peter Levitch                                                                      WA2-34           10,000
-----------------------------------------------------------------------------------------------------------
Platinum Long Term Growth                                                          WA2-35           13,333
-----------------------------------------------------------------------------------------------------------
ProMed Offshore Fund, Ltd.                                                         WA2-36           14,600
-----------------------------------------------------------------------------------------------------------
ProMed Partners II, L.P.                                                           WA2-37           19,560
-----------------------------------------------------------------------------------------------------------
ProMed Partners, L.P.                                                              WA2-38           90,200
-----------------------------------------------------------------------------------------------------------
RHP Master Fund, Ltd.                                                              WA2-39           40,000
-----------------------------------------------------------------------------------------------------------
Richard Reiss                                                                      WA2-40            5,000
-----------------------------------------------------------------------------------------------------------
Ritchie Long/Short Trading Ltd.                                                    WA2-41          100,000
-----------------------------------------------------------------------------------------------------------
Robert J. and Sandra S. Neborsky JTWROS                                            WA2-42            4,000
-----------------------------------------------------------------------------------------------------------
Robert J. Neborsky, MD, Inc. Combination Retirement Trust U/T/A 11/30/82           WA2-43           52,000
-----------------------------------------------------------------------------------------------------------
Robert Wexler                                                                      WA2-44            2,000
-----------------------------------------------------------------------------------------------------------
Roland Hartman                                                                     WA2-58            5,000
-----------------------------------------------------------------------------------------------------------
Saad Investments Company Limited                                                   WA2-45           30,000
-----------------------------------------------------------------------------------------------------------
Schroder & Co Bank AG                                                              WA2-59           90,000
-----------------------------------------------------------------------------------------------------------
SDS Capital Group SPC, Ltd.                                                        WA2-46          133,333
-----------------------------------------------------------------------------------------------------------
Sean M. Quinn                                                                      WA2-47           14,000
-----------------------------------------------------------------------------------------------------------
SF Capital Partners Ltd.                                                           WA2-48          100,000
-----------------------------------------------------------------------------------------------------------
Stonestreet LP                                                                     WA2-49           46,666
-----------------------------------------------------------------------------------------------------------
Sunrise Overseas, Ltd.                                                             WA2-50           33,200
-----------------------------------------------------------------------------------------------------------
TCMP3 Partners                                                                     WA2-51           20,000
-----------------------------------------------------------------------------------------------------------
Wayne Saker                                                                        WA2-52            8,000
-----------------------------------------------------------------------------------------------------------
Whalehaven Fund Limited                                                            WA2-53           16,666
-----------------------------------------------------------------------------------------------------------
William B. Newman                                                                  WA2-54            6,800
-----------------------------------------------------------------------------------------------------------
Xmark Fund, L.P.                                                                   WA2-55           33,000
-----------------------------------------------------------------------------------------------------------
Xmark Fund, LTD                                                                    WA2-56           33,000
-----------------------------------------------------------------------------------------------------------
</TABLE>REGISTRATION RIGHTS AGREEMENT

         This Registration Rights Agreement (this "Agreement"), dated as of
April 5, 2004 (the "Agreement Date"), is among ADVENTRX Pharmaceuticals, Inc., a
Delaware corporation (the "Company"), each of the persons and entities listed on
Schedule 1 hereto (each, an "Investor").

                                   BACKGROUND

         A. The Company and the Investors (other than Burnham Hill Partners)
have entered into a Common Stock and Warrant Purchase Agreement (the "Purchase
Agreement") as of the Agreement Date pursuant to which the Company desires to
sell to the Investors and the Investors desire to purchase from the Company
shares of Common Stock, par value $0.001 per share ("Common Stock"), of the
Company (the "Shares").

         B. As additional consideration for the purchase of the Shares, pursuant
to the Purchase Agreement, the Company shall issue to the Investors certain
warrants to purchase shares of Common Stock, and, in consideration of services
as placement agent, the Company shall issue to Burnham Hill Partners certain
warrants to purchase shares of Common Stock (collectively, the "Warrants").

         C. A condition to the obligations under the Purchase Agreement is that
the Company and the Investors enter into this Agreement in order to provide the
Investors with certain rights to register the resale of the Shares.

                                    AGREEMENT

         In consideration of the mutual promises,  representations,  warranties,
covenants  and  conditions  set forth in this  Agreement,  the parties  agree as
follows:

1.        Definitions. For purposes of this Agreement, the term:

         (a)      "Registrable Securities" means (a) the Shares and the Warrant
                  Shares or other securities issued or issuable to each Investor
                  or its transferee or designee (i) upon exercise of the
                  Warrants, or (ii) upon any dividend or distribution with
                  respect to, any exchange for or any replacement of the Shares,
                  Warrants or Warrant Shares or (iii) upon any conversion,
                  exercise or exchange of any securities issued in connection
                  with any such distribution, exchange or replacement; (b)
                  securities issued or issuable upon any stock split, stock
                  dividend, recapitalization or similar event with respect to
                  the foregoing; (c) securities issued pursuant to Section 8 or
                  Section 9 of the Purchase Agreement, Section 9 or Section 10
                  of this Agreement or Section 3 of the Warrants and (d) any
                  other security issued as a dividend or other distribution with
                  respect to, in exchange for, in replacement or redemption of,
                  or in reduction of the liquidation value of, any of the
                  securities referred to in the preceding clauses.

         (b)      "Commission" means the Securities and Exchange Commission.

         (c)      "Warrant Shares" means the shares of Common Stock issuable
                  upon exercise of the Warrants.

                                       1
<PAGE>

         (d)      "Securities Act" means the Securities Act of 1933, as amended.

2.       Filing of Registration Statement.

                  (a) The Company shall prepare and file with the Commission a
         "shelf" registration statement (a "Registration Statement") on Form S-3
         (or if such form is not available to the Company on another form
         appropriate for such registration in accordance herewith) covering all
         Registrable Securities for a secondary or resale offering to be made on
         a continuous basis pursuant to Rule 415, such Registration Statement to
         be filed by no later than June 30, 2004 (the "Target Filing Date"). The
         Company shall use its best efforts to cause the Registration Statement
         to be declared effective under the Securities Act not later than 90
         days after the Target Filing Date (including filing with the Commission
         a request for acceleration of effectiveness in accordance with Rule 461
         promulgated under the Securities Act within five business days of the
         date that the Company is notified (orally or in writing, whichever is
         earlier) by the Commission that a Registration Statement will not be
         "reviewed," or not be subject to further review) and to keep such
         Registration Statement continuously effective under the Securities Act
         until such date as is the earlier of (x) the date when all Registrable
         Securities covered by such Registration Statement have been sold or (y)
         the second anniversary of the Agreement Date (the "Effectiveness
         Period"). Upon the initial filing thereof, the Registration Statement
         shall cover at least 100% of the Shares and 100% of the Warrant Shares.
         Such Registration Statement also shall cover, to the extent allowable
         under the Securities Act and the Rules promulgated thereunder
         (including Securities Act Rule 416), such indeterminate number of
         additional shares of Common Stock resulting from stock splits, stock
         dividends or similar transactions with respect to the Registrable
         Securities. Not less than three business days prior to the filing of
         the Registration Statement or any related prospectus or any amendment
         or supplement thereto, the Company shall (i) furnish to counsel to SDS
         Management, LLC ("SDS"), copies of all such documents proposed to be
         filed, which documents (other than those incorporated by reference)
         will be subject to the review of such counsel, and (ii) at the request
         of any holder of Registrable Securities cause its officers and
         directors, counsel and independent certified public accountants to
         respond to such inquiries as shall be necessary, in the reasonable
         opinion of counsel to such holders, to conduct a reasonable
         investigation within the meaning of the Securities Act. The Company
         shall not file the Registration Statement or any such prospectus or any
         amendments or supplements thereto to which the holders of a majority of
         the Registrable Securities or counsel to SDS shall reasonably object in
         writing within three business days after their receipt thereof.

                  (b) The Company shall (i) prepare and file with the Commission
         such amendments, including post-effective amendments, to the
         Registration Statement as may be necessary to keep the Registration
         Statement continuously effective as to all Registrable Securities for
         the Effectiveness Period and to the extent any Registrable Securities
         are not included in such Registration Statement for reasons other than
         the failure of the Holder to comply with Section 4 hereof, shall
         prepare and file with the Commission such additional Registration
         Statements in order to register for resale under the Securities Act all
         Registrable Securities; (ii) cause the related prospectus to be amended
         or supplemented by any required prospectus supplement, and as so
         supplemented or amended to be filed pursuant to Rule 424 (or any

                                       2
<PAGE>

         similar provisions then in force) promulgated under the Securities Act;
         (iii) respond as promptly as possible, and in no event later than 10
         business days, to any comments received from the Commission with
         respect to the Registration Statement or any amendment thereto and as
         promptly as possible, upon request, provide counsel for SDS true and
         complete copies of all correspondence from and to the Commission
         relating to the Registration Statement; and (iv) comply in all material
         respects with the provisions of the Securities Act and the Exchange Act
         with respect to the disposition of all Registrable Securities covered
         by the Registration Statement during the applicable period in
         accordance with the intended methods of disposition by the Investors
         thereof set forth in the Registration Statement as so amended or in
         such prospectus as so supplemented.

                  (c) The Company shall notify the holders of Registrable
         Securities to be sold and counsel to SDS as promptly as possible (i)
         when a prospectus or any prospectus supplement or post-effective
         amendment to the Registration Statement is proposed to be filed (but in
         no event in the case of this subparagraph (i), less than three business
         days prior to the date of such filing); (ii) when the Commission
         notifies the Company whether there will be a "review" of such
         Registration Statement; and (iii) with respect to the Registration
         Statement or any post-effective amendment, when the same has become
         effective, and after the effectiveness thereof: (A) of any request by
         the Commission or any other Federal or state governmental authority for
         amendments or supplements to the Registration Statement or prospectus
         or for additional information; (B) of the issuance by the Commission of
         any stop order suspending the effectiveness of the Registration
         Statement covering any or all of the Registrable Securities or the
         initiation of any proceedings for that purpose; (C) of the receipt by
         the Company of any notification with respect to the suspension of the
         qualification or exemption from qualification of any of the Registrable
         Securities for sale in any jurisdiction, or the initiation or
         threatening of any proceeding for such purpose; and (D) if the
         financial statements included in the Registration Statement become
         ineligible for inclusion therein or of the occurrence of any event that
         makes any statement made in the Registration Statement or prospectus or
         any document incorporated or deemed to be incorporated therein by
         reference untrue in any material respect or that requires any revisions
         to the Registration Statement, prospectus or other documents so that,
         in the case of the Registration Statement or the prospectus, as the
         case may be, it will not contain any untrue statement of a material
         fact or omit to state any material fact required to be stated therein
         or necessary to make the statements therein, in the light of the
         circumstances under which they were made, not misleading. Without
         limitation to any remedies to which the Investors may be entitled under
         this Agreement, if any of the events described in Section 2(c)(iii)
         occur, the Company shall use its best efforts to respond to and correct
         the event.

                  (d) Each Investor acknowledges that the Registration Statement
         shall also register a significant amount of shares of Common Stock
         owned by other stockholders which have "piggy-back" registration rights
         under various agreements with the Company.

                                       3
<PAGE>
3.       Piggy-back Registration.

                  (a) Right to Piggy-back. If (but without any obligation to do
         so other than as provided above) the Company proposes to register any
         of shares of Common Stock in connection with any offering of shares of
         Common Stock pursuant to a registration statement under the Securities
         Act (other than a registration relating solely to the sale of
         securities to participants in a Company stock plan or a transaction
         covered by Rule 145 under the Securities Act, or a registration in
         which the only stock being registered is Common Stock issuable upon
         conversion of debt securities which are also being registered) (a
         "Public Offering"), the Company shall promptly give each Investor
         written notice of such registration, at least 10 business days prior to
         the filing of any registration statement under the Securities Act. Upon
         the written request of the Investor given within 5 business days after
         delivery of such written notice by the Company, the Company shall,
         subject to the provisions of Section 3(b) below, use its best efforts
         to cause to be registered under the Securities Act on such registration
         statement all of the Registrable Securities that the Investor has
         requested to be registered.

                  (b) Underwriting. If the registration statement under which
         the Company gives notice under Section 3(a) is for an underwritten
         Public Offering, the Company shall so advise the Investor. The right of
         the Investor to registration pursuant to Section 3(a) above shall be
         conditioned upon the Investor's participation in such underwriting and
         the inclusion of the Registrable Securities in the underwriting to the
         extent provided herein. The Investor shall (together with the Company
         and any other holders of Company securities distributing their
         securities through such underwriting) enter into an underwriting
         agreement in customary form with the underwriter or underwriters
         selected for underwriting by the Company. Notwithstanding any other
         provision of Sections 3(a), if the underwriter determines that
         marketing factors require a limitation of the number of shares to be
         underwritten, the underwriter may exclude some or all of the
         Registrable Securities from such registration and underwriting.

4. Furnish Information. It shall be a condition to the Company's obligations to
take any action under this Agreement with respect to the Registrable Securities
of any Investor that the Investor shall promptly furnish to the Company, upon
request, such information regarding itself, the Registrable Securities, and the
intended method of disposition of such securities as shall be necessary to
effect the registration of their Registrable Securities. In that connection,
each selling Investor shall be required to represent to the Company that all
such information which is given is both complete and accurate in all material
respects when made.

5. Delay of Registration. The Investor shall have no right to obtain or seek an
injunction restraining or otherwise delaying any such registration as the result
of any controversy that might arise with respect to the interpretation or
implementation of the terms of this Agreement.

6. Termination of Registration Rights. The Company shall have no obligation to
register the Registrable Securities pursuant to this Agreement or otherwise
following the end of the Effectiveness Period.

                                       4
<PAGE>

7.       Indemnification.

                  (a) To the extent permitted by law, the Company shall,
         notwithstanding any termination of this Agreement, indemnify and hold
         harmless each Investor, the officers, directors, agents and employees
         of each of them, each Person who controls any such Investor (within the
         meaning of Section 15 of the Securities Act or Section 20 of the
         Exchange Act) and the officers, directors, agents and employees of each
         such controlling Person, to the fullest extent permitted by applicable
         law, from and against any and all losses, claims, damages, liabilities,
         costs (including, without limitation, costs of preparation and
         reasonable attorneys' fees) and expenses (collectively, "Losses"), as
         incurred, arising out of or relating to any untrue or alleged untrue
         statement of a material fact contained or incorporated by reference in
         the Registration Statement, any prospectus or any form of prospectus or
         in any amendment or supplement thereto or in any preliminary
         prospectus, or arising out of or relating to any omission or alleged
         omission of a material fact required to be stated therein or necessary
         to make the statements therein (in the case of any prospectus or form
         of prospectus or amendment or supplement thereto, in the light of the
         circumstances under which they were made) not misleading (collectively
         a "Violation"), provided, however, that the indemnity agreement
         contained in this Section 7(a) shall not apply to amounts paid in
         settlement of any such Loss if such settlement is effected without the
         prior written consent of the Company (which consent shall not be
         unreasonably withheld), nor shall the Company be liable to any Investor
         or officer, director, agent or controlling person thereof to the extent
         that any Loss arises out of or is based upon untrue statements,
         omissions or violations which occur in reliance upon and in conformity
         with information furnished expressly for use in connection with such
         registration by any such Investor or officer, director or agent thereof
         or any controlling person.

                  (b) To the extent permitted by law, each Investor shall,
         notwithstanding any termination of this Agreement, indemnify and hold
         harmless the Company, each of its directors, each of its officers who
         has signed the registration statement, each person, if any, who
         controls the Company (within the meaning of Section 15 of the
         Securities Act or Section 20 of the Exchange Act), any underwriter, any
         other stockholder of the Company selling securities in such
         Registration Statement and any controlling person of any such
         underwriter or other stockholder, against any Losses, as incurred,
         arising out of or relating to any Violation in each case to the extent
         that such Violation occurs in reliance upon and in conformity with
         written information furnished expressly for use in connection with such
         registration by any such Investor or officer, director, agent or
         controlling person thereof ; provided, however, that the indemnity
         agreement contained in this Section 7(b) shall not apply to amounts
         paid in settlement of any such Loss if such settlement is effected
         without the consent of the Investor, which consent shall not be
         unreasonably withheld. Notwithstanding anything to the contrary
         contained herein, the Investor shall be liable under this Section 7(b)
         for only that amount as does not exceed the net proceeds to such
         Investor as a result of the sale of Registrable Securities pursuant to
         such Registration Statement.

8. Listing. The Company shall cause all Registrable Securities to be listed on
any United States securities exchange, quotation system, market or
over-the-counter bulletin board on which similar securities issued by the
Company are then listed and use its best efforts to maintain such listing.

                                       5
<PAGE>

9. Failure to File Registration Statement. The Company and the Investors agree
that the Investors will suffer damages if the Registration Statement is not
filed on or prior to the Target Filing Date and maintained in the manner
contemplated herein during the Effectiveness Period. The Company and the
Investors further agree that it would not be feasible to ascertain the extent of
such damages with precision. Accordingly, if the Registration Statement is not
filed on or prior to the Target Filing Date, the Company shall pay in cash or in
shares of Common Stock (at the Company's option) as liquidated damages for such
failure and not as a penalty to each Investor an amount equal to two percent
(2%) of the total purchase price such Investor paid for the Shares and Warrants
purchased pursuant to the Purchase Agreement (the "Total Purchase Price") for
each 30-day period until the Registration Statement has been filed with the
Commission, which shall be pro rated for such periods less than 30 days (the
"Late Filing Damages"). Payments to be made to an Investor pursuant to this
Section 9 shall be due and payable within 5 business days of any demand therefor
by such Investor, but in no event more than once during any 30-day period. The
parties agree that the Late Filing Damages represent a reasonable estimate on
the part of the parties, as of the date of this Agreement, of the amount of
damages that may be incurred by the Investors if the Registration Statement is
not filed on or prior to the Target Filing Date. If the Company elects to pay
the Late Filing Damages in shares of Common Stock, such shares of Common Stock
shall be valued at the average closing price of a share of Common Stock on the
applicable trading market for the Common Stock for the 5-trading-day period
immediately preceding the date of demand of such Late Filing Damages.

10. Failure of Registration Statement to Become Effective. The Company and the
Investors agree that the Investors will suffer damages if the Registration
Statement is not declared effective by the Commission on or prior to the
ninetieth (90th) day following the Target Filing Date (the "Effectiveness
Deadline"). The Company and the Investors further agree that it would not be
feasible to ascertain the extent of such damages with precision. Accordingly, if
the Registration Statement is not declared effective by the Commission prior to
the Effectiveness Deadline, the Company shall pay in cash or in shares of Common
Stock (at the Company's option) as liquidated damages for such failure and not
as a penalty to each Investor an amount equal to (a) two percent (2%) of such
Investor's Total Purchase Price for the first 30-day period following the
Effectiveness Deadline (which shall be pro rated for such periods less than 30
days) and (b) one percent (1%) of such Investor's Total Purchase Price for each
subsequent 30-day period (which shall be pro rated for such periods less than 30
days) (the "Non-Effectiveness Damages") until either (x) the Registration
Statement is declared effective by the Commission or (y) the first anniversary
of the Agreement Date. Payments to be made to an Investor pursuant to this
Section 10 shall be due and payable within 5 business days of any demand
therefor by such Investor, but in no event more than once during any 30-day
period. The parties agree that the Non-Effectiveness Damages represent a
reasonable estimate on the part of the parties, as of the date of this
Agreement, of the amount of damages that may be incurred by the Investors if the
Registration Statement is not declared effective on or prior to the ninetieth
(90th) day following the Target Filing Date. If the Company elects to pay the
Non-Effectiveness Damages in shares of Common Stock, such shares of Common Stock
shall be valued at the average closing price of a share of Common Stock on the
applicable trading market for the Common Stock for the 5-trading-day period
immediately preceding the date of demand of such Non-Effectiveness Damages.

                                       6
<PAGE>

11.      Listing; Exchange Act Reports.

                  (a) The Company shall use commercially reasonable best efforts
         to list its Common Stock on the American Stock Exchange.

                  (b) With a view to making available to the Investors the
         benefits of Rule 144 promulgated under the Securities Act or any other
         similar rule or regulation of the Commission that may at any time
         permit the investors to sell securities of the Company to the public
         without registration ("Rule 144"), the Company agrees to:

                           (i) make and keep public information available, as
                           those terms are understood and defined in Rule 144;

                           (ii) file with the Commission in a timely manner all
                           reports and other documents required of the Company
                           under the Securities Act and the Securities Exchange
                           Act of 1934, as amended (the "Exchange Act") so long
                           as the Company remains subject to such requirements
                           and the filing of such reports and other documents is
                           required for the applicable provisions of Rule 144;
                           and

                           (iii)furnish to each Investor so long as such
                           Investor owns Registrable Securities, promptly upon
                           request, (i) a written statement by the Company that
                           it has complied with the reporting requirements of
                           Rule 144, the Securities Act and the Exchange Act,
                           (ii) a copy of the most recent annual or quarterly
                           report of the Company and such other reports and
                           documents so filed by the Company to the extent any
                           such report is not available on the Commission's
                           website, and (iii) such other information as may be
                           reasonably requested to permit the Investors to sell
                           such securities pursuant to Rule 144 without
                           registration.

12.      Miscellaneous.

                  (a) Governing Law. This Agreement, all acts and transactions
         pursuant hereto and the rights and obligations of the parties hereto
         shall be governed, construed and interpreted in accordance with the
         laws of the state of California, without giving effect to principles of
         choice of law.

                  (b) Jurisdiction and Venue. Any legal action or other legal
         proceeding relating to this Agreement or the enforcement of any
         provision of this Agreement shall be brought or otherwise commenced in
         any state or federal court located in the county of San Diego,
         California. Each party to this Agreement: (i) expressly and irrevocably
         consents and submits to the jurisdiction of each state and federal
         court located in the county of San Diego, California and each appellate
         court located in the state of California, in connection with any such
         legal proceeding; (ii) agrees that each state and federal court located
         in the county of San Diego, California shall be deemed to be a
         convenient forum; and (iii) agrees not to assert, by way of motion, as
         a defense or otherwise, in any such legal proceeding commenced in any
         state or federal court located in the county of San Diego, California
         any claim that such party is not subject personally to the jurisdiction
         of such court, that such legal proceeding has been brought in an
         inconvenient forum, that the venue of such proceeding is improper or
         that this Agreement or the subject matter of this Agreement may not be
         enforced in or by such court.

                                       7
<PAGE>

                  (c) Entire Agreement. This Agreement embodies the entire
         agreement and understanding between the parties hereto with respect to
         the subject matter hereof and supersedes all prior oral or written
         agreements and understandings relating to the subject matter hereof. No
         statement, representation, warranty, covenant or agreement of any kind
         not expressly set forth in this Agreement shall affect, or be used to
         interpret, change or restrict, the express terms and provisions of this
         Agreement.

                  (d) Notices. All notices and other communications hereunder
         shall be in writing and shall be given (and shall be deemed to have
         been duly given upon receipt) by delivery in person or facsimile
         transmission (received at the facsimile machine to which it is
         transmitted prior to 5:00 p.m., local time, on a business day in the
         state of California, for the party to which it is sent), by courier or
         express delivery service or by registered or certified mail (postage
         prepaid, return receipt requested) to the respective parties at the
         following addresses (or at such other address for a party as shall be
         specified in a notice given in accordance with this Section):

<TABLE>
<CAPTION>
<S>     <C>                                                  <C>
        if to the Company:                                   ADVENTRX Pharmaceuticals, Inc.
                                                             9948 Hibert Street, Suite 100
                                                             San Diego, CA  92131
                                                             Attention: Nicholas J. Virca
                                                             Facsimile: (858) 271-9678
        with a copy to (not to constitute notice):           Bingham McCutchen LLP
                                                             3 Embarcadero Center
                                                             San Francisco, CA  94111-4067
                                                             Attention: Henry D. Evans, Jr.
                                                             Facsimile: (415) 393-2286

        if to the Investor:                                  To the address set forth in Schedule 1 hereto.
</TABLE>

                  (e) Amendments and Waivers. Any term of this Agreement may be
         amended, waived or departed from only with the written consent of the
         Company and the holders of a majority of the Registrable Securities
         then outstanding. Any amendment or waiver effected in accordance with
         this Section 12(e) shall be binding upon each party to this Agreement,
         whether or not such party has signed such amendment or waiver and the
         Company. No such waiver or consent shall be deemed to be or shall
         constitute a waiver or consent with respect to any other terms or
         provisions of this Agreement, whether or not similar. Each such waiver
         or consent shall be effective only in the specific instance and for the
         purpose for which it was given, and shall not constitute a continuing
         waiver or consent.

                  (f) Successors and Assigns. This Agreement is personal to each
         of the parties and may not be assigned without the written consent of
         the other parties; provided, however, that any of the Investors shall
         be permitted to assign this Agreement to any person to whom it assigns
         or transfers the Warrants or Registrable Securities, other than in a
         public resale, in compliance with applicable securities laws. Any
         assignee must be an "accredited investor" as defined in Rule 501(a)
         promulgated under the Securities Act.

                                       8
<PAGE>

                  (g) Severability. In the event that any court of competent
         jurisdiction shall determine that any provision, or any portion
         thereof, contained in this Agreement shall be unenforceable in any
         respect, then such provision shall be deemed limited to the extent that
         such court deems it enforceable, and as so limited shall remain in full
         force and effect. In the event that such court shall deem any such
         provision, or portion thereof, wholly unenforceable, the remaining
         provisions of this Agreement shall nevertheless remain in full force
         and effect.

                  (h) Interpretation. The parties hereto acknowledge and agree
         that: (i) each party and such party's counsel has reviewed the terms
         and provisions of this Agreement; (ii) the rule of construction to the
         effect that any ambiguities are resolved against the drafting party
         shall not be employed in the interpretation of this Agreement; and
         (iii) the terms and provisions of this Agreement shall be construed
         fairly as to the parties hereto and not in favor of or against any
         party, regardless of which party was generally responsible for the
         preparation of this Agreement. Whenever used herein, the singular
         number shall include the plural, the plural shall include the singular,
         the use of any gender shall include all persons.

                  (i) Headings and Captions. The headings and captions of the
         various subdivisions of this Agreement are for convenience of reference
         only and shall in no way modify, or affect the meaning or construction
         of any of the terms or provisions hereof.

                  (j) No Waiver of Rights, Powers and Remedies. No failure or
         delay by a party hereto in exercising any right, power or remedy under
         this Agreement, and no course of dealing between the parties hereto,
         shall operate as a waiver of any such right, power or remedy of the
         party. No single or partial exercise of any right, power or remedy
         under this Agreement by a party hereto, nor any abandonment or
         discontinuance of steps to enforce any such right, power or remedy,
         shall preclude such party from any other or further exercise thereof or
         the exercise of any other right, power or remedy hereunder. The
         election of any remedy by a party hereto shall not constitute a waiver
         of the right of such party to pursue other available remedies. No
         notice to or demand on a party not expressly required under this
         Agreement shall entitle the party receiving such notice or demand to
         any other or further notice or demand in similar or other circumstances
         or constitute a waiver of the rights of the party giving such notice or
         demand to any other or further action in any circumstances without such
         notice or demand.

                  (k) Registration Expenses. All fees and expenses incident to
         the performance of or compliance with this Agreement by the Company
         shall be borne by the Company whether or not the Registration Statement
         is filed or becomes effective and whether or not any Registrable
         Securities are sold pursuant to the Registration Statement. The fees
         and expenses referred to in the foregoing sentence shall include,
         without limitation, (i) all registration and filing fees (including,
         without limitation, fees and expenses (A) with respect to filings
         required to be made with the American Stock Exchange and each other
         securities exchange, quotation system, market or over-the-counter
         bulletin board on which Registrable Securities are required hereunder
         to be listed, (B) with respect to filings required to be made with the
         Commission, and (C) in compliance with state securities or Blue Sky
         laws, (ii) printing expenses (including, without limitation, expenses
         of printing certificates for Registrable Securities and of printing or
         photocopying prospectuses), (iii) messenger, telephone and delivery
         expenses, (iv) Securities Act liability insurance, if the Company so

                                       9
<PAGE>

         desires such insurance, (v) fees and expenses of all other persons
         retained by the Company in connection with the consummation of the
         transactions contemplated by this Agreement, including, without
         limitation, the Company's independent public accountants (including, in
         the case of an underwritten offering, the expenses of any comfort
         letters or costs associated with the delivery by independent public
         accountants of a comfort letter or comfort letters) and legal counsel,
         and (vi) fees and expenses of the counsel to SDS, up to $5,000, in
         connection with any Registration Statement hereunder. In addition, the
         Company shall be responsible for all of its internal expenses incurred
         in connection with the consummation of the transactions contemplated by
         this Agreement (including, without limitation, all salaries and
         expenses of its officers and employees performing legal or accounting
         duties), the expense of any annual audit, the fees and expenses
         incurred in connection with the listing of the Registrable Securities
         on any securities exchange as required hereunder.

                  (l) Counterparts and Facsimile Delivery. This Agreement may be
         executed in counterparts, each of which shall be deemed an original,
         but all of which together shall constitute one and the same instrument.
         Any signature page delivered by facsimile or other electronic image
         transmission shall be binding to the same extent as an original
         signature page, with regard to any agreement subject to the terms
         hereof or any amendment thereto. Any party who delivers such a
         signature page agrees to later deliver an original counterpart to any
         party who requests it.

                  (m) Independent Nature of Investors' Obligations and Rights.
         The obligations of each Investor under this Agreement are several and
         not joint with the obligations of any other Investor, and no Investor
         shall be responsible in any way for the performance of the obligations
         of any other Investor under any such agreement. Nothing contained
         herein, and no action taken by any Investor pursuant thereto, shall be
         deemed to constitute the Investors as a partnership, an association, a
         joint venture or any other kind of entity, or create a presumption that
         the Investors are in any way acting in concert or as a group with
         respect to such obligations or the transactions contemplated by such
         agreement. Each Investor shall be entitled to independently protect and
         enforce its rights, including without limitation, the rights arising
         out of this Agreement, and it shall not be necessary for any other
         Investor to be joined as an additional party in any proceeding for such
         purpose. Each Investor represents that it has been represented by its
         own separate legal counsel in its review and negotiation of this
         Agreement. For reasons of administrative convenience only, the
         Investors acknowledge and agree that they and their respective counsel
         have chosen to communicate with the Company through Wiggin and Dana
         LLP, but Wiggin and Dana LLP does not represent any of the Investors in
         this transaction other than SDS (an affiliate of an Investor).

                            [Signature page follows.]

                                       10
<PAGE>

         IN WITNESS WHEREOF,  the parties hereto have executed this Agreement as
of the date first above written.

ADVENTRX PHARMACEUTICALS, INC.

By: /s/ Nicholas J. Virca
   -------------------------

Name: Nicholas J. Virca
   -------------------------
Title: President and Chief Executive Officer

[Investor signature pages follow.]

           Company Signature page to the Registration Rights Agreement

                                       11
<PAGE>

INVESTORS:

Print Exact Name: [see attached schedule for list of investors party to this
                  agreement]

By:_____________________________________________
Name:
Title:

                    [ADVENTRX Registration Rights Agreement]

                                       12
<PAGE>

                                   SCHEDULE 1

                                    INVESTORS

Alpha Capital AG
--------------------------------------------------------------------------------
Anasazi Partners III LLC
--------------------------------------------------------------------------------
Anasazi Partners III Offshore Fund Ltd.
--------------------------------------------------------------------------------
Andrew J. Maffey
--------------------------------------------------------------------------------
Bank Sal. Oppenheim jr. & Cie (Switzerland) Limited
--------------------------------------------------------------------------------
BayStar Capital II, L.P.
--------------------------------------------------------------------------------
Bristol Investment Fund, Ltd.
--------------------------------------------------------------------------------
BSI New BioMedical Frontier (SICAV)
--------------------------------------------------------------------------------
BSI SA
--------------------------------------------------------------------------------
Capital Ventures International
--------------------------------------------------------------------------------
Castle Creek Healthcare Partners LLC
--------------------------------------------------------------------------------
Centrum Bank AG
--------------------------------------------------------------------------------
Christopher P. Baker
--------------------------------------------------------------------------------
Clariden Investments Ltd.
--------------------------------------------------------------------------------
Crescent International Ltd
--------------------------------------------------------------------------------
Crestview Capital Master, LLC
--------------------------------------------------------------------------------
E Todd Tracy
--------------------------------------------------------------------------------
Enable Growth Partners
--------------------------------------------------------------------------------
Gamma Opportunity Capital Partners, LP
--------------------------------------------------------------------------------
Gene Salkind, MD
--------------------------------------------------------------------------------
Greenwich Growth Fund Limited
--------------------------------------------------------------------------------
James Ladner
--------------------------------------------------------------------------------
JIBS Equities
--------------------------------------------------------------------------------
Kenneth Greif
--------------------------------------------------------------------------------
Laddcap Value Partners LP
--------------------------------------------------------------------------------
LB (Swiss) Privatbank AG
--------------------------------------------------------------------------------
Lilienthal Investment Foundation
--------------------------------------------------------------------------------
Longview Fund, LP
--------------------------------------------------------------------------------
Michael Loew
--------------------------------------------------------------------------------
North Sound Legacy Fund LLC
--------------------------------------------------------------------------------
North Sound Legacy Institutional Fund LLC
--------------------------------------------------------------------------------
North Sound Legacy International Ltd
--------------------------------------------------------------------------------
OTAPE Investments LLC
--------------------------------------------------------------------------------
Paul Scharfer
--------------------------------------------------------------------------------
Peter Levitch
--------------------------------------------------------------------------------
Platinum Long Term Growth
--------------------------------------------------------------------------------
ProMed Offshore Fund, Ltd.
--------------------------------------------------------------------------------
ProMed Partners II, L.P.
--------------------------------------------------------------------------------
ProMed Partners, L.P.
--------------------------------------------------------------------------------
RHP Master Fund, Ltd.
--------------------------------------------------------------------------------
Richard Reiss
--------------------------------------------------------------------------------
Ritchie Long/Short Trading Ltd.
--------------------------------------------------------------------------------
Robert J. and Sandra S. Neborsky JTWROS
--------------------------------------------------------------------------------
Robert J. Neborsky, MD, Inc. Combination Retirement Trust U/T/A 11/30/82
--------------------------------------------------------------------------------
Robert Wexler
--------------------------------------------------------------------------------
Roland Hartman
--------------------------------------------------------------------------------
Saad Investments Company Limited
--------------------------------------------------------------------------------
Schroder & Co Bank AG
--------------------------------------------------------------------------------
SDS Capital Group SPC, Ltd.
--------------------------------------------------------------------------------
Sean M. Quinn
--------------------------------------------------------------------------------
SF Capital Partners Ltd.
--------------------------------------------------------------------------------
Stonestreet LP
--------------------------------------------------------------------------------
Sunrise Overseas, Ltd.
--------------------------------------------------------------------------------
TCMP3 Partners
--------------------------------------------------------------------------------
Wayne Saker
--------------------------------------------------------------------------------
Whalehaven Fund Limited
--------------------------------------------------------------------------------
William B. Newman
--------------------------------------------------------------------------------
Xmark Fund, L.P.
--------------------------------------------------------------------------------
Xmark Fund, LTD

                                       13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]